Clinigen
As of the edition of 20 October 2026, Clinigen runs 15 drugs, 15 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 15 |
| Total | 15 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Carboplatin | none listed | 0 |
| Tacrolimus anhydrous | Ends 2028 (exclusivity) | 3 |
| Aldesleukin | Ended 2005 (orphan exclusivity) | 2 |
| Sodium chloride | none listed | 0 |
| Calcium | none listed | 0 |
| Dexrazoxane | none listed | 5 |
| Zinc sulfate | none listed | 0 |
| Foscarnet | none listed | 0 |
| Calcium gluconate | none listed | 0 |
| Potassium citrate anhydrous | none listed | 0 |
| Calcium chloride | none listed | 0 |
| Sodium citrate | none listed | 0 |
| Potassium | none listed | 0 |
| Idursulfase beta | none listed | 0 |
| Calcium glycerophosphate | none listed | 0 |
A route B row is one company at one target.